MMSL 2014, 83(1):18-27 | DOI: 10.31482/mmsl.2014.004
NON-NEWTONIAN SUSPENSION FORMULATIONS FOR IMPROVED STABILITY AND DELIVERY OF AUTOINJECTABLE CBRN COUNTERMEASURESOriginal article
- Microencapsulation and Nanomaterials Department, Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX
Autoinjectors are commonly employed by the United States and other countries to deliver emergency therapeutics to counteract the effects of various chemical agent threats, including nerve agents. Autoinjector combination products (autoinjector and drug product) used by the military can have drawbacks, including insufficient thermal stability of drug products, limited aqueous solution concentration of active pharmaceutical ingredients (APIs), and complicated and expensive designs for delivering multiple drugs simultaneously. We have developed a novel Enhanced Formulation (EF) technology that solves these problems, using nanoparticle suspensions in biocompatible cottonseed oil (CSO) instead of aqueous solutions of API. The hydrophobic CSO prevents hydrolytic degradation by limiting exposure to water, and the noninteraction of co-suspended particles simplifies multi-drug cocktail therapies. The high API loading (10% or more) gives the formulations non-Newtonian rheological behavior, with high zero-shear viscosity to resist sedimentation, and shear thinning to allow injection with standard autoinjectors and needles.
Keywords: Organophosphate; MMB4; nanoparticle; milling; intramuscular injection; formulation; particle size; suspension; non-Newtonian; shear thinning; enhanced formulation; nerve agent antidote; nerve agent intoxication; medical countermeasure; cottonseed oil
Received: October 28, 2013; Revised: March 23, 2014; Published: April 7, 2014 Show citation
References
- U.S. National Library of Medicine. Retrieved from http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=4211
- Shih, T-M.; Koplovitz, I.; Kan, Robert K.; McDonough, John H. In Search of an Effective in vivo Reactivator for Organophosphorus Nerve Agent-Inhibited Acetylcholinesterase in the Central Nervous System. Adv. Stud. Bio. 2012, 4, 10, 451-478.
- Antonijevic, B; Stojiljkovic, M.P. Unequal Efficacy of Pyridinium Oximes in Acute Organophosphate Poisoning. Clin. Med. Res. 2007, 5, 1, 71-82.
Go to original source...
Go to PubMed...
- Lundy, P.M.; Hamilton, M.G.; Sawyer, T.W.; Mikler, J. Comparative protective effects of HI-6 and MMB-4 against organophosporous nerve agent poisoning. Toxicology. 2011, 285, 3, 90-96.
Go to original source...
Go to PubMed...
- H. Thiermann, R. Schreiner, P. Eyer. Dissolution kinetics of unstable drugs in two-compartment autoinjectors: Analysis of the individual shaking behaviour and influence of various shaking parameters on the dissolution rate of HI 6 in an automated system. Inter. J. Pharm. 1998, 170, 23-32.
Go to original source...
- Dixon, H.; Clark, A.P.-Z.; Cabell, L.A.; McDonough, J. MMB4 DMS Nanoparticle Suspension Formulation With Enhanced Stability for the Treatment of Nerve Agent Intoxication. Inter. J. Toxicol. 2013, 32(S2), 18S-29S.
Go to original source...
Go to PubMed...
- Clark, A.P-Z.; Dixon, H.; Cantu, N.L.; Cabell, L.A.; McDonough, J.A. Good Manufacturing Practice: Manufacturing of a Nerve Agent Antidote Nanoparticle Suspension. Inter. J. Toxicol. 2013, 32(S2), 5S-17S.
Go to original source...
Go to PubMed...
- Battelle Study MMB4-09-1001 S-12-08. A Phase 1 Double-Blind, Placebo-Controlled, Single-Center Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intramuscular Administration of a New Oxime, MMB4 Dimethanesulfonate (DMS) Enhanced Formulation (EF). Conducted for: U.S. Army Medical Research and Materiel Command. 2012.
- Barnes, H.A. Thixotropy - a Review. J. Non-Newtonian Fluid Mech. 1997, 70, 1-33.
Go to original source...
- Determined by computational fluid dynamics modeling using FLUENT 6.3. The range of shear rates was determined by varying parameters such as needle gauge and injection speed.